Fibralign set to bring new device option for secondary lymphedema

Jun 26, 2014

A young company developing a product to address secondary lymphedema, a chronic disease with no cure, stole the show at a venture competition held during a recent medical device conference. Working with Stanford University (Stanford, California), Fibralign (Sunnyvale, California) developed BioBridge, a surgical device designed to support the formation of new functional lymphatic vessels.

The company has completed a large animal study to validate the technology and is now preparing for a clinical study. Fibralign was voted the winner of the annual MedTech Innovator competition by an audience at the 22nd annual medical device conference hosted by law firm Wilson Sonsini Goodrich & Rosati (WSGR). The company won prizes valued at $150,000, including $100,000 in cash provided by RCT Ventures, $25,000 in cash provided by Johnson & Johnson Development Corporation, and $25,000 worth of lab space at Janssen Labs.

Medical Device Daily | Today’s Headlines

A young company developing a product to address secondary lymphedema, a chronic disease with no cure, stole the show at a venture competition held during a recent medical device conference. Working with Stanford University (Stanford, California), Fibralign (Sunnyvale, California) developed BioBridge, a surgical device designed to support the formation of new functional lymphatic vessels.

The company has completed a large animal study to validate the technology and is now preparing for a clinical study. Fibralign was voted the winner of the annual MedTech Innovator competition by an audience at the 22nd annual medical device conference hosted by law firm Wilson Sonsini Goodrich & Rosati (WSGR). The company won prizes valued at $150,000, including $100,000 in cash provided by RCT Ventures, $25,000 in cash provided by Johnson & Johnson Development Corporation, and $25,000 worth of lab space at Janssen Labs.

Read more.

Fibralign Sponsors International Research Seminar

Fibralign Sponsors International Research Seminar

Fibralign is hosting the inaugural Lymphedema Summit on January 23-   Fibralign is hosting the inaugural Lymphedema Summit on January 23, an international research seminar focused on “Advancements in Lymphedema Surgical Treatment.” For more details:...

read more
Fibralign Selected as a UCSF Rosenman Institute Innovator

Fibralign Selected as a UCSF Rosenman Institute Innovator

NCI-funded study evaluating Fibralign’s BioBridge® as an adjunct to microsurgical treatment SAN FRANCISCO, June 10, 2021 /PRNewswire/ -- The UCSF Rosenman Institute is proud to announce the 2021 cohort of the Rosenman Innovators, a group of early-stage health...

read more